Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies. According to the company, its goal is to significantly improve outcomes for people living with cancer by designing therapies that selectively activate within the tumor microenvironment, thereby achieving durable efficacy without the severe systemic side effects associated with systemically active I-O agents. The company's core technology is a clinically-validated masking platform. Xilio engineers highly potent biologics that remain masked, or inactive, until they reach the tumor microenvironment, where they are unmasked, or activated, by tumor-specific matrix metalloproteases (MMPs) and other tumor-specific proteases. This integrated biology and protein engineering approach is intended to confine therapeutic activity to the tumor site. Xilio states that it is advancing multiple programs in preclinical and clinical development for masked multi-specifics. The company also reports that its masking technology has enabled top-tier strategic partnerships, including collaborations with AbbVie and Gilead. Leadership includes René Russo, Pharm.D., who serves as President, Chief Executive Officer and Board Member, and Uli Bialucha, Ph.D., who serves as Chief Scientific Officer. Dr. Russo is described as an accomplished biotechnology CEO with over 25 years of experience in biopharmaceutical R&D and commercialization, including a key role in building Cubist Pharmaceuticals. Dr. Bialucha has served as Xilio's chief scientific officer since August 2022 and joined the company as senior vice president of research in April 2021. Xilio Therapeutics is headquartered in the United States and operates primarily in the U.S. biopharmaceutical market. The company positions itself within the immuno-oncology segment of the biotechnology industry, emphasizing tumor-selective activation as a differentiator from systemically active I-O agents.

Xilio Therapeutics is a clinical-stage biotechnology company that has built its identity around a tumor-selective masking technology for immuno-oncology therapies. The company describes itself as discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer. The central premise of Xilio's approach is that systemically active I-O agents can cause severe side effects, and that confining therapeutic activity to the tumor microenvironment could improve the therapeutic window. To pursue this, Xilio developed an integrated biology and protein engineering approach that enables the design of highly potent, masked biologics. These molecules remain masked, or inactive, until they reach the tumor microenvironment, where they are unmasked, or activated, by tumor-specific matrix metalloproteases (MMPs) and other tumor-specific proteases. Xilio states that its masking technology is clinically validated and that it is advancing multiple programs in preclinical and clinical development for masked multi-specifics. The company also reports that its technology has enabled top-tier strategic partnerships, including with AbbVie and Gilead. On the leadership side, Uli Bialucha, Ph.D., joined Xilio as senior vice president of research in April 2021 and has served as chief scientific officer since August 2022. Before joining Xilio, Dr. Bialucha was vice president of drug discovery at Immunitas Therapeutics, where he led development of a single-cell genomics-based discovery platform and an immuno-oncology-focused therapeutic pipeline. René Russo, Pharm.D., serves as President, Chief Executive Officer and Board Member. Dr. Russo is described as having over 25 years of experience leading R&D and commercialization in the biopharmaceutical industry across multiple therapeutic areas, including oncology, and as having played a key role in building Cubist Pharmaceuticals, which Merck acquired for $9.6B in 2015. Xilio Therapeutics is headquartered in the United States and operates in the biotechnology and immuno-oncology sector. The company's public communications emphasize its pipeline, its masking technology platform, and its strategic partnerships as core elements of its business.

• Uli Bialucha, Ph.D. joined Xilio as Senior Vice President of Research.

• Uli Bialucha, Ph.D. became Chief Scientific Officer of Xilio.

Clinical-stage biotechnology company developing tumor-selective masked immuno-oncology therapies designed to activate only in the tumor microenvironment, aiming for durable efficacy without severe systemic side effects.

• Masked immuno-oncology therapies

  Biologics designed to remain inactive until unmasked by tumor-specific proteases in the tumor microenvironment.

• Masked multi-specifics

  Preclinical and clinical programs for masked multi-specific biologics.

• 2020.07.23

  Reported2020.07.23

  Xilio Therapeutics appoints Paul J. Clancy to its board[4]Xilio Therapeutics任命Paul J. Clancy加入董事会biospace.com

  Xilio Therapeutics announced the appointment of Paul J. Clancy to its Board of Directors.

• 2020.06.17

  Reported2020.06.17

  Xilio Therapeutics appoints Daniel S. Lynch as board chair[5]Xilio Therapeutics任命Daniel S. Lynch为董事会主席biospace.com

  Xilio Therapeutics announced that Daniel S. Lynch was appointed chair of its board of directors.

Read more

1. 1Xilio Therapeutics | Tumor-selective Immunotherapyxiliotx.com
2. 2Our Leadership Team, Board, and Advisors | Xilio Therapeuticsxiliotx.com
3. 3Xilio Therapeutics (United States) - Wikidatawikidata.org
4. 4Xilio Therapeutics任命Paul J. Clancy加入董事会biospace.com
5. 5Xilio Therapeutics任命Daniel S. Lynch为董事会主席biospace.com